StreetAlpha.app
Home › Stocks › BBOT

BridgeBio Oncology Therapeutics, Inc. (BBOT)

$1.81
▼ −2.69%
LAST CLOSE · NOV 20

BridgeBio Oncology Therapeutics develops oral cancer drug candidates that target KRAS and PI3Kα signaling. It last closed at $1.81 on Nov 20, down 2.69% on the day. The next earnings report for BBOT is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, BBOT reported EPS of -$0.43. Over its last 5 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months BBOT insiders bought $0 of stock on the open market and sold $4K, according to SEC Form 4 filings.

AI Auto Pilots
Is BBOT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BBOT.

Key Stats

Last 12 months
Results
Net income
−$171.5M
Free cash flow
−$151.0M
Valuation
Market cap
$145.3M
80.3M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$76.5M
At Sep 30
Shareholder equity
$293.4M
Shares outstanding
80.3M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$42K−$42KFY2023FY2024: −$74.3M−$74.3MFY2024FY2025: −$134.0M−$134.0MFY2025

From BBOT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · After the close
Reported EPS
-$0.43
Quarter ended Sep 2026
Year ago EPS
-$1.03
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$833.69Dec '24Mar 2025: -$54.23Mar '25Jun 2025: -$566.46Jun '25Sep 2025: -$1.03Sep '25Dec 2025: $2.19Dec '25Mar 2026: -$526.11Mar '26Jun 2026: -$705.20Jun '26Sep 2026: -$0.43Sep '26Latest -$0.43
Revenue by quarter
Not enough quarters on file yet.
How BBOT moved after its last 5 reports
Average move the session after a report ±5.3%
Nov 10, 2026After the close+16.4%
Aug 11, 2026After the close+2.4%
May 12, 2026After the close−0.6%
Mar 5, 2026After the close+5.4%
Nov 12, 2025After the close−2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BBOTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BBOT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BBOT

Technical Analysis

BBOT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 26% below its 20 day and 73% below its 50 day average. It is 309% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $1.78, and the nearest resistance the Pivot at $1.84.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.0%/day
Key levels
$14.8752 week high+721.5%
$7.40200 day average+308.8%
$5.89100 day average+225.4%
$3.1450 day average+73.5%
$2.68Swing high (Nov 12)+48.1%
$2.2820 day average+26.0%
$1.91Pivot R1+5.5%
$1.84Pivot+1.7%
$1.81Last close
$1.7852 week low−1.7%
$1.75Pivot S1−3.3%
Indicators
RSI (14)28.93Oversold below 30Oversold
MACD-0.42Above its signal lineBullish
Stochastic4.1Near the bottom of its rangeOversold
ADX (14)49.1Strong downtrend
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-126.1Oversold below −100, overbought above 100Oversold
Rate of change−11.3%Change over 10 sessionsBearish
ATR (14)$0.25Typical daily range, 14.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BBOT

What happened before

See how BBOT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for BBOTHow many large options trades hit BBOT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BBOT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲56 buying vs 29 selling
  • ▲Held by funds +1.4 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8966+34.8%
In funds' top 1054+25.0%
Held by funds75.1%73.7%+1.4 pts
New / increased33 / 2317 / 21+47.4%
Reduced / sold out20 / 915 / 18−12.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BBOT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BBOT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4K2 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-11 sold $4KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Pedro BeltranPresident and CEOSale plan1,870$1.84$3K
Nov 13Marc CoboPrincipal Accounting OfficerSale plan78$2.37$185
Every insider buy and sale for BBOT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BBOT insider trades →

From SEC Form 4 filings by BBOT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBOT is in one of them and how their past BBOT trades turned out.

BBOT in the AI portfolios
Loading…

BBOT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BBOT in an article yet. Here's the latest on the wider market.

BBOT in the news

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics is a biotechnology company based in South San Francisco, California, that is developing oral small molecule drugs for cancer. Its pipeline targets KRAS, a protein that is mutated in many cancers, and PI3Kα, a signaling protein that RAS proteins activate. The company is designing its drug candidates for patients with lung, breast, pancreatic and colorectal cancers, and it is testing them in early stage clinical trials.

Headquarters
South San Francisco, CA